Kaken Pharmaceutical Co., Ltd. (4521.T)

3.478,00 +1,00 (+0,03%) Börsenschluss: 03:15PM JST

Kaken Pharmaceutical Co., Ltd.

28-8, Honkomagome 2-chome
Bunkyo-ku
Tokyo 113-8650
Japan
81 3 5977 5007
https://www.kaken.co.jp

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.130

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Hiroyuki Horiuchi	President & Representative Director	N/A	N/A	N/A
Mr. Tomoyuki Koseki	Chief Officer of Marketing & Sales Division	N/A	N/A	N/A
Naoyuki Ishida	GM of Human Resources Department & Corporate Officer	N/A	N/A	N/A
Satoshi Murakami	Chief Officer of Regulatory Affairs Division	N/A	N/A	N/A
Mr. Masanao Shimano Ph.D.	Chief Officer of Production Division, Chief of Shizuoka Factory & Corporate Officer	N/A	N/A	N/A
Mr. Hironobu Ogura	Chief of Drug Research Centers	N/A	N/A	N/A
Mr. Masashi Suzudo	GM of Corporate Planning & Coordination Department and Director	N/A	N/A	1962
Hirofumi Fujii	Corporate Officer	N/A	N/A	N/A
Mitsuru Watanuki	Chief Officer of R&D Division and Corporate Officer	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in JPY.

Beschreibung

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Corporate Governance

Kaken Pharmaceutical Co., Ltd.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 8, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.